121 results about "Cytokine expression" patented technology

The invention relates to the use of gelsolin to treat infections and to monitor the treatment of infections. The invention also provides methods up-regulating interleukin expression and methods for down-regulating pro-inflammatory cytokine expression.

The present invention relates to molecules that stabilize and / or enhance CD154 activity, compositions comprising these molecules, methods for using these molecules and compositions (e.g., pharmaceutical compositions) comprising them. Specifically, the molecules can be used for enhancing immune function (e.g., enhancing Th1 cytokine expression), stimulating immune responses, and / or treating certain disorders (e.g., cancer, infectious disease, and immune compromised states). The invention also relates to kits and compositions comprising the molecules.

The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and / or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.

The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and / or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.

Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and / or IL-23.

Methods and compositions disclosed herein generally relate to methods of providing or enhancing a diagnosis of eosinophilic esophagitis (EE). In particular, the invention relates to obtaining a sample from a patient having at least one indication of EE, then quantifying from the sample an amount of one or more cytokines associated with EE or an mRNA corresponding to the cytokine or its receptor, wherein an altered level of the cytokine or mRNA correlates with a positive diagnosis of EE. An EE diagnosis can then be provided or enhanced, based upon the quantifying step. The invention further relates to diagnostic kits, tests, and / or arrays that can be used to quantify the one or more cytokines associated with EE or an mRNA corresponding to the cytokine or its receptor.

The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and / or isolated from a single plant or multiple plants to a host in need thereof. The present also includes a novel method for simultaneously inhibiting expression of pro-inflammatory cytokines, preventing ROS generation and augmenting anti-oxidant defenses. The activity of this composition is conducive to ultimately preserving cognitive function and providing a level of neuroprotection.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means suchas viral infections like HIV and AIDS, or the development of neoplasms in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing ThI cytokine expression, decreasing Th2 cytokine expression, increasing ERK phosphorylation, inducing apoptosis in malignant cells, inducing remission, maintaining remission, as chemotherapeutic agents, as well as for decreasing symptoms of cytopathic diseases and opportunistic infections that may accompany such diseasesl. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols, therapeutic agents used to treat opportunistic infections due to HIV, or chemotherapeutic agents to yield more effective treatment tools against cytopathic diseases in mammalian subjects.

The invention discloses a new secretive cytokine NS128 of human beings, which relates to a coding amino acid sequence of the cytokine or the polynucleotide of the cytokine fragment, containing a genetic engineering carrier and a host cell of the polynucleotide. The invention also relates to a production method of the amino acid sequence of the cytokine or the polypeptide of the cytokine fragment and the production method of the polypeptide as well as a small interference RNA, which suppresses the expression of the cytokine. The invention also relates to a salt which contains the polynucleotide or the salt of acceptable drugs, or a medical composition of the polypeptide or the salt of acceptable drugs. The invention further relates to applications of the polynucleotide of the cytokine, the polypeptide or the small interference RNA in preparation of prevention and / or treatment medicines for tumor, infection, hematopoietic disorder and autoimmune disease, etc., in particular having clinical implications for tumor, inflammation and nervous system disease and so on related to MAPK signal pathway. The invention also relates to a method of in vitro testing whether the expression of the polynucleotide or the polypeptide changes. The invention also relates to a monoclonal or polyclonal antibody which is specifically bound with the polypeptide or an active fragment of the polypeptide.

The invention relates to the use of gelsolin to treat infections and to monitor the treatment of infections. The invention also provides methods up-regulating interleukin expression and methods for down-regulating pro-inflammatory cytokine expression.

The present invention provides an ex vivo method of treating plasmacytoid dendritic cells (pDC) in Th2- or Th17-associated diseases by modulating the cytokine expression or secretion using interferon lambda (IFN-λ). For the Th-2 or Th17-associated diseases, pDC cells from a patient having the disease are exposed ex vivo with IFN-λ in an effective amount to inhibit cytokine releases. The IFN-λ exposed pDC are administered back into the patient. The present invention also provides a method of ex vivo IFN-λ treatment of pDC, in conjunction with co-administration of a composition comprising IFN-λ.

Methods and a composition for the treatment of organ dysfunction, acute renal failure, multi-organ failure, early dysfunction of kidney transplant, graft rejection, chronic renal failure, wounds, and inflammatory disorders including media conditioned by mesenchymal stem cells are provided. Methods for modulation of growth factor and cytokine expression including administering a therapeutic amount of mesenchymal stem cells, endothelial cells derived from mesenchymal stem cells, or media conditioned by mesenchymal stem cells are also provided.

The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and / or isolated from a single plant or multiple plants to a host in need thereof. The present also includes a novel method for simultaneously inhibiting expression of pro-inflammatory cytokines, preventing ROS generation and augmenting anti-oxidant defenses. The activity of this composition is conducive to ultimately preserving cognitive function and providing a level of neuroprotection.

The present invention is based, at least in part, on the discovery of methods useful in the modulation, e.g., inhibition, of gene expression or protein activity, e.g., apoptosis-related gene expression, e.g., Fas gene expression or cytokine expression, e.g., proinflammatory cytokine expression. In particular, the present invention is based on novel RNA interfering agents, e.g., siRNA in reduction, e.g., prolonged reduction, of apoptosis-related gene expression or cytokine expression in cells. Inhibition of apoptosis-related gene expression or protein activity or cytokine gene expression or protein activity, e.g. by the siRNAs used in the methods of the invention, inhibits ischemia-reperfusion injury.

The present disclosure relates to the finding that microRNA-146 plays a role in modulating the development and function of the immune system. Immune cell development and function can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells or precursor cells. For example, in some embodiments, activity and / or proliferation of certain immune cells is regulated by administering miR-146 oligonucleotides or anti-miR-146 oligonucleotides. In other embodiments, pro-inflammatory cytokine expression in immune cells is regulated by administering a miR-146 oligonucleotide or anti-miR-146. In further embodiments, methods of regulating macrophage activity using antisense miR-146 are provided. Additional methods and compositions for regulating immune system function and development using miR-146 are disclosed.

The invention belongs to the biomedical field and discloses a method for obtaining regulatory macrophage in vitro and relates to a method for obtaining new regulatory macrophage by virtue of induction of endothelial matrix cells of spleen. Specifically, the material used in the method comprises endothelial matrix cells of spleen and bone marrow mononuclear cells of a mouse. The matrix cells and the bone marrow mononuclear cells are co-cultured, so that the bone marrow mononuclear cells are differentiated into macrophage a molecular marker for expressing the macrophage is characterized by high expressive CD45RB and medium expressive CD11c. Moreover, the macrophage has a cytokine expression spectrum which is similar to that of an M2b macrophage. Dependent on ESSC contact culture, the macrophage can secrete high-level IL-10 and inhibit T cell proliferation and induce T apoptosis in vitro; verified through experiments, the macrophage sorted by the method has the characteristics of the regulatory macrophage. The method provides a new method for obtaining high-secretion IL-10 macrophage by in-vitro massive induction and can be applied to experiments and clinic.

The invention belongs to the field of biomedicine, and relates to a novel medicinal purpose of a traditional Chinese medicine effective component icariin. The invention specifically relates to a purpose of icariin in the preparation of medicines used for treating bronchial asthma. Test results show that, icariin assists in ameliorating asthma rat lung tissue inflammations, inhibiting inflammatory in asthma rat blood serum, inhibiting inflammatory in asthma rat alveolar lavage fluid, regulating expression unbalance of asthma rat lung tissue Th1 / Th2 relevant cytokine, and regulating expression unbalance of asthma rat lung tissue Th1 / Th2 relevant transcription factor (T-bet / GATA-3). The traditional Chinese medicine effective component icariin provided by the invention can be adopted as an active component, and can be prepared with pharmaceutically acceptable carriers into medicine compositions used for bronchial asthma.

This present invention is directed to peptides, compositions, and methods for modulating endogenous cytokine expression in a subject. More specifically, the invention provides peptides useful in regulating the release of a specific pattern of cytokines that promote angiogenesis and / or can be used to modulate the immune system of a subject.

The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and / or isolated from a single plant or multiple plants to a host in need thereof. The present also includes a novel method for simultaneously inhibiting expression of pro-inflammatory cytokines, preventing ROS generation and augmenting anti-oxidant defenses. The activity of this composition is conducive to ultimately preserving cognitive function and providing a level of neuroprotection.

The present invention is directed to a family of therapeutic peptides capable of modulating cytokine expression and / or stimulating the immune system of subject without producing or sustaining serious side-effects. Methods using the peptides to modulate cytokine expression in a subject, treat a disease, enhance vaccination, and stimulate a subject's immune system response are also disclosed.

The invention discloses a rapid screening method and application of bifidobacterium capable of relieving colitis and belongs to the technical field of biology. The bifidobacterium pseudocatenulatum is preserved in China Center for Type Culture Collection (CCTCC), Wuhan, on July 5, 2021, and the preservation number is CCTCC M2021820. The bifidobacterium pseudocatenulatum can be used for significantly improving weight loss, colon length and disease activity index of mice during DSS-inducing colitis, enhancing intestinal barrier integrity, and inhibiting tissue damage, myeloperoxidase (MPO) activity, PGE2 level and proinflammatory factors. Compared with mice of a model group, the bifidobacterium pseudocatenulatum KLDS N2 has the advantages that the expression of proinflammatory cytokine mRNA of a DSS stimulated mouse is obviously down-regulated, and the expression of mRNA of mucoprotein and tight junction protein is up-regulated.

A method for treating an inflammatory condition or immune disorder comprises administering to a subject having such a condition or disorder a therapeutically effective amount of at least one compound selected from irindalone, physiologically active enantiomers thereof, and pharmaceutically acceptable salts thereof. The invention further provides a method for elevating levels of anti-inflammatory cytokines such as IL-10 and IL-13 while inhibiting expression of pro-inflammatory cytokines. A pharmaceutical composition, useful for example in topical treatment of psoriasis, comprises a therapeutically effective amount of at least one compound selected from irindalone, physiologically active enantiomers thereof, and pharmaceutically acceptable salts thereof, in a vehicle comprising at least one pharmaceutically acceptable excipient, the vehicle being adapted for topical administration to skin of a subject.

A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia, ischemia, brain inflammation or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with transient cerebral hypoxia, ischemia, brain inflammation or a TBI, and within 24 hours of onset of the condition, administering to the subject a continuous intravenous infusion dose of methamphetamine in an amount sufficient to reduce the occurrence of brain cell damage or death caused by the condition. Preferably, the dose is increased in response to a delay in administration. The invention also relates to a method for modulating cytokine expression within the brain to treat such conditions.

The present invention discloses a method for classifying individuals into those who have airway hyperreactvitiy and those with asthma based on cytokine expression patterns. It is contemplated that such a method will enable rapid identification of individuals requiring intensive treatment for asthma, thereby reducing morbidity and improving quality of life for those affected.

The invention discloses a core-shell coaxial nanofiber for repairing a periodontitis bone defect, a preparation method thereof and a use thereof. Pluronic F127 is taken as a raw material, resveratrolis taken as a model drug, resveratrol polymer micelles is prepared by a film hydration process, and core-shell coaxial nanofibers loaded with resveratrol and bone morphogenetic protein-2 (BMP-2) is prepared by coaxial electrospinning. Because the core and shell layers of the fiber were loaded with drugs with different biological activities and functions at the same time, the drug release order andconcentration in the core and shell layers are adjusted by regulating the structure of nanofibers, the combined use of drugs is achieved, the inhibition of lipopolysaccharide (LPS)-induced inflammatory cytokines expression in periodontal ligament cells and the inhibition of osteoclast differentiation in RAW264.7 cells provide a new approach for the treatment of periodontal disease.